Stocks

9% Risk-Free Return in 1 Month: See How I Did It

September 25, 2011

It’s very rare that you hear the phrase “risk-free return” these days without it being tied to an FDIC-insured CD yielding south of 3%.  Heck, even US Treasuries are no longer considered risk-free by S&P following the recent credit downgrade and there are only 4 AAA companies left in the S&P500.  So, you’re probably thinking […]

Read the full article →

AAA Companies in the S&P500 – Only 4 Left!

August 14, 2011

AAA companies in the S&P500 index are now numbered at just 4 following the rating downgrade of Berkshire Hathaway earlier in the year.  Amazingly, these companies and dozens of sovereigns are now rated higher than US Treasury Bonds following Fitch’s downgrade of US debt: The US Has Lost its AAA Credit Rating – Here’s What […]

Read the full article →

You Should NOT Be Losing Sleep Over This Market Crash

August 8, 2011

Markets are in turmoil and may well be for the foreseeable future.  Over the past few weeks, we’ve had the confluence of a burgeoning debt crisis in the Euro region with the impending debt ceiling deadline looming.  The deal the President and Congress agreed to was not digested well by global markets or by one […]

Read the full article →

ImmunoCellular Therapeutics (IMUC) Review

July 27, 2011

Today we’re going to take a look at an interesting prospect in the early stage Biotech world – ImmunoCellular Therapeutics (IMUC). Company Profile ImmunoCellular Therapeutics an oncology firm based in California whose lead candidate ICT-107 is entering Phase II for patients with glioblastoma multiforme (GBM) which is a specific type of brain cancer.  IMUC’s lead […]

Read the full article →

Portfolio Update – I Tripled the S&P500 – Again!

July 20, 2011

Wow, it’s been a long time since I’ve shared a portfolio update.  Since last update was in October (all portfolio updates here), it’s only fair to compare the performance of my holdings at that time from October to present versus the S&P500. So, if you held the same shares I did since last update (and […]

Read the full article →

CytRx Corporation Stock Review

May 24, 2011

Today we’re going to take a look at an interesting prospect in the early stage Biotech world – CytRx Corporation (ticker: CYTR).  CytRx is focused on oncology drugs and has three primary drug candidates in the mid-late stage pipeline phases with prospects for various indications. Pipeline Review Here’s a recent snapshot of the pipeline indicating […]

Read the full article →

← Previous Entries

Next Entries →